Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders

Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders

US Patent 9580438 · Granted Feb 28, 2017

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chro2022
3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase i2021
KV1.3 inhibitors and their medical application2020
Kv1.3 inhibitors and their medical application2020
Method of inhibiting DYRK1B2020
Heterocyclic compounds with working memory enhancing activity2019
2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors2018
2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors2018
Method of inhibiting DYRK1B2018
Substituted bicyclic heterocyclic compounds as gamma secretase modulators2015
Substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine deri2014
Calcium salts of compounds as anti-inflammatory, immunomodulatory and anti-proli2014